Table 4 Clinical trials using semaphorins/semaphorin receptors as targets for the therapy of cancer
From: SEMAPHORINS and their receptors: focus on the crosstalk between melanoma and hypoxia
ClinicalTrials.gov Identifier | Recruitment status | Aim of the trial | Cancer histotype |
|---|---|---|---|
NCT01313065 Phase 1 | Completed | Safety, tolerability, pharmacokinetics and pharmacodynamics of anti-Semaphorin 4D neutralizing monoclonal antibody, VX15/2503 (Pepinemab) | Advanced solid tumors (Patnaik A et al Clin Cancer Res 2016) |
Completed | Safety and tolerability of VX15/2503 in combination with avelumab | Advanced non-small cell lung cancer | |
Phase 1, Phase 2 | |||
Recruiting | Efficacy of VX15/2503 in combination with ipilimumab or nivolumab | Stage I-IVA head and neck squamous cell cancer | |
Phase 1 | |||
Recruiting | Efficacy of VX15/2503 with or without ipilimumab or nivolumab | Resectable stage I-III pancreatic and stage IV colorectal cancer | |
Phase 1 | |||
Recruiting | Efficacy of VX15/2503 with or without ipilimumab and/or nivolumab | Resectable Stage IIIB-D Melanoma | |
Phase 1 | |||
Active, not recruiting | Efficacy of VX15/2503 with nivolumab or ipilimumab | Stage III or IV Melanoma | |
Phase I | |||
Completed | Dose-limiting toxicities of anti-Neuropilin1 neutralizing monoclonal antibody, MNRP1685A | Locally advanced or metastatic solid tumors (Weekes CD et al Invest New Drugs 2014) | |
Phase 1 | |||
Completed | Efficacy of MNRP1685A in combination with bevacizumab with or without paclitaxel | Locally advanced or metastatic solid tumors (Patnaik A et al CancerChemotherapyPharmacology 2014) | |
Phase 1 |